Stock Price Quote

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE1002.20-17.15 (-1.68 %)
PREV CLOSE ( ) 1019.35
OPEN PRICE ( ) 1009.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 70478
TODAY'S LOW / HIGH ( )994.45 1019.00
52 WK LOW / HIGH ( )660.05 1059.6
NSE1002.70-17 (-1.67 %)
PREV CLOSE( ) 1019.70
OPEN PRICE ( ) 1001.00
BID PRICE (QTY) 1002.70 (85)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1195996
TODAY'S LOW / HIGH( ) 993.85 1019.35
52 WK LOW / HIGH ( )726.8 1059
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-09 1981
Management Info
V C Nannapaneni - Chairman V C Nannapaneni - Managing Director
Registered Office

Address Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040-23547532

Email investors@natcopharma.co.in / dasaradhi@natcopharma.co.in

Website www.natcopharma.co.in

Registrars Details
Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
 Listing : BSE, NSE

NEWS

06Mar NATCO Pharma informs about analyst me
Pursunt to Regulation 30 of SEBI (Listing Obligations and Disclosure Req..
04Mar Natco Pharma launches Pomalidomide cap
Natco Pharma, along with its partner Breckenridge Pharmaceutical, has la..
04Mar Natco Pharma rises on launching Pomali
Natco Pharma is currently trading at Rs. 965.00, up by 8.60 points or 0...
25Feb Natco Pharma informs about clarificati
Natco Pharma has clarified that they made all necessary disclosures purs..
25Feb Clarification sought from Natco Pharm
The Exchange has sought clarification from Natco Pharma Ltd on February..
MORE

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit106918504
Gross Profit 1252 22260
Operating Profit 175624656
Net Sales 528840945
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Emcure Pharma (BSE)
peergroup  1519.85 (7.43%)
M.Cap ( in Cr)28814.77
Torrent Pharma (BSE)
peergroup  4370.80 (1.46%)
M.Cap ( in Cr)147927.73
Venus Remedies (BSE)
peergroup  755.25 (7.31%)
M.Cap ( in Cr)1009.54
Fredun Pharma (BSE)
peergroup  1577.60 (2.83%)
M.Cap ( in Cr)846.54
Kwality Pharma (BSE)
peergroup  1492.95 (2.91%)
M.Cap ( in Cr)1549.11
MORE

Shareholding Pattern

PROMOTERS 49.48%
FI/BANKS/INSURANCE 3.5%
NON-INSTITUTION 29.97%
MUTUAL FUNDS/UTI 1.6%
GOVERNMENT 0%
FII 0%
MORE

About Natco Pharma Ltd.

Natco Pharma Ltd. was incorporated in the year 1981. Its today's share price is 1002.2. Its current market capitalisation stands at Rs 17950.39 Cr. In the latest quarter, company has reported Gross Sales of Rs. 42350 Cr and Total Income of Rs.44180 Cr. The company's management includes Lakshminarayana Bolisetty, Nitin Jain, Kantipudi Suma, Dronadula Vijaya Bhaskar, ADM Chavali, D Linga Rao, PSRK Prasad, Rajeev Nannapaneni, V C Nannapaneni, V C Nannapaneni, Chekuri Venkat Ramesh.

It is listed on the BSE with a BSE Code of 524816 , NSE with an NSE Symbol of NATCOPHARM and ISIN of INE987B01026. It's Registered office is at Natco House,Road No 2,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Brahmayya & Co, BSR & Associates LLP, BSR & Co, Walker Chandiok & Co LLP, Walker, Chandiok & Co, Walker, Chandiok & Co LLP

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – February 2026 Online Grievance Portal – SCORES Online Dispute Resolution Portal – ODR Fee Calculator UPI ID - QR Code & Forms Contact Us
Mutual Funds About Nirmal Bang Wealth Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data Important Update
Other Links Disclaimer Privacy Policy Policies and Procedures Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI Scores RMS Policy Inspection SORM Policy - NBEPL CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023 FY-2023-2024 FY-2024-2025
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker RA NBEPL Investor Charter RA NBSPL Investor Charter Investor Complaints -RA Investor Complaints-NBEPL Investor NBCPL Investor NBEPL RA Investor NBSPL-RA
Evoting
NSDL Evoting CDSL Evoting
Compliance Annual report
NBSPL ACR Report Signed Annexure – NBSPL NBEPL ACR Report Signed Annexure – NBEPL
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’s Surrendered List of AP’s KYC Activation Process Voluntary Freezing Blocking of Online Trading Account Internal Shortage Policy MCXCCL Client Reports Policy For GTC/GTD RBI Guidelines Transfer of Funds via SEBI-Validated UPI ID
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatment NBSPL Policy of AML NBEPL Policy of AMLNBSPL Policy of SurveillanceNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For Any Legal Department Grievances – Level 1, Please Get In Touch With Mr. Bhavin Pandya On 022-6273 9232 Or Write A Mail To bhavin.pandya@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Legal Department Grievances – Level 2, Please Get In Touch With Mr. Kishor Kumar Agrawal On 022-6273 9252/9253 Or Write A Mail To kishorkumar.agrawal@nirmalbang.com With Subject line As Grievances/Complaint.     |     For Any Compliance Grievances / other grievances , Please Get In Touch With Mr. Samir Kamdar On 022-62739395/9396 Or Write A Mail To samir.kamdar@nirmalbang.com With Subject line As Grievances/Complaint.     |    
IMPORTANT LINKS: SEBI BSE NSE MCX CDSL NSDL NCDEX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.